Open | - |
Close | - |
Volume / Avg. | 0 / 1.214M |
Day Range | - - - |
52 Wk Range | 6.860 - 27.350 |
Market Cap | $288.821M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 30 |
Short Interest | 13.62% |
Days to Cover | 9.29 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of RAPT Therapeutics (NASDAQ: RAPT) through any online brokerage.
Other companies in RAPT Therapeutics’s space includes: bluebird bio (NASDAQ:BLUE), TScan Therapeutics (NASDAQ:TCRX), Opthea (NASDAQ:OPT), Monte Rosa Therapeutics (NASDAQ:GLUE) and Century Therapeutics (NASDAQ:IPSC).
The latest price target for RAPT Therapeutics (NASDAQ: RAPT) was reported by UBS on Thursday, February 22, 2024. The analyst firm set a price target for 10.00 expecting RAPT to rise to within 12 months (a possible 20.48% upside). 21 analyst firms have reported ratings in the last year.
The stock price for RAPT Therapeutics (NASDAQ: RAPT) is $8.3 last updated March 18, 2024 at 6:59 PM EDT.
There are no upcoming dividends for RAPT Therapeutics.
RAPT Therapeutics’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for RAPT Therapeutics.
RAPT Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.